At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 127 enrolled
Drug / intervention
rLP2086 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Observer-blinded, Parallel-group, Active-control, Phase ½ Trial Of The Safety, Immunogenicity, And Tolerability Of 20 Mg, 60 Mg, And 200 Mg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years
In Brief
A Phase 2 clinical trial evaluating rLP2086 for Healthy. Completed, enrolled 127 participants across 9 sites.
Detailed Summary
Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartNov 2006
Primary CompletionJan 2008
Study CompletionFeb 2008
TodayJul 2026
First PostedOct 13, 2006
Enrollment StartNov 1, 2006
Primary CompletionJan 1, 2008
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.7 years ago
Interventions
rLP2086biological
Vaccine administered at 0, 1, and 6 months
rLP2086biological
Vaccine administered at 0, 1, and 6 months
rLP2086biological
Vaccine administered at 0, 1, and 6 months
rLP2086biological
Vaccine administered at 0, 1, and 6 months